<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04567160</url>
  </required_header>
  <id_info>
    <org_study_id>2021-2343</org_study_id>
    <nct_id>NCT04567160</nct_id>
  </id_info>
  <brief_title>NOL Index to Compare the Intraoperative Analgesic Effect of Propofol Versus Sevoflurane</brief_title>
  <acronym>PROSEVNOL</acronym>
  <official_title>Use of the NOL Index to Compare the Intraoperative Analgesic Effect of Propofol Versus Sevoflurane After Standardized Stimulation in Patients Under General Anesthesia. The PROSEVNOL Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ciusss de L'Est de l'Île de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ciusss de L'Est de l'Île de Montréal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective randomized controlled study is to compare the analgesic&#xD;
      properties of propofol and sevoflurane using variation of the NOL index and standard&#xD;
      monitoring (Heart Rate and Mean Arterial Blood Pressure) when patients under general&#xD;
      anaesthesia with either agents are subjected to a standardized painful stimulus (a tetanic&#xD;
      stimulation over the ulnar nerve at 70 mA, 100 Hz for 30 seconds).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study proposes a research design that compare the analgesic properties of two commonly&#xD;
      used agents for induction and maintenance of the hypnotic component of anesthesia: propofol&#xD;
      versus sevoflurane. Using the NOL index to quantitatively monitor nociception, it is expected&#xD;
      to see a difference in response to a standardized electrical and tetanic stimulus during&#xD;
      general anesthesia maintained with either agents.&#xD;
&#xD;
      Hypothesis is that magnitude of the variation and/or the value of the NOL Index following a&#xD;
      standardized nociceptive stimulus is lower when general anesthesia is based on propofol&#xD;
      rather than on sevoflurane.&#xD;
&#xD;
      Induction of general anesthesia will differ depending in which group the patient belongs.&#xD;
&#xD;
      In the propofol group, general anesthesia will be induced using target-controlled infusion&#xD;
      (TCI) of propofol and remifentanil.&#xD;
&#xD;
      In the sevoflurane group, induction of general anesthesia will be carried out by spontaneous&#xD;
      breathing through a mask while progressively opening up the dial of the sevoflurane vaporizer&#xD;
      up to 8%. Like in the propofol group, target-controlled infusion of remifentanil is&#xD;
      simultaneously started to reach an initial target predicted effect-site concentration of 3&#xD;
      ng/mL. Vaporizer is adjusted when gas equilibration reaches the patient-specific&#xD;
      concentration 1.0 MAC of sevoflurane.&#xD;
&#xD;
      At this point, noxious stimulation will be delayed at least 10 minutes after TCI remifentanil&#xD;
      is paused to allow for the remifentanil to be cleared out and to ensure brain-alveolar&#xD;
      equilibration of sevoflurane (sevoflurane group).&#xD;
&#xD;
      Measurements of the NOL Index, BIS, HR and MAP start 1 minute before applying noxious&#xD;
      stimulus (prestimulation period). Means of the data collected during that period will&#xD;
      constitute the basal values for NOL and HR before stimulation. After this stand-by period,&#xD;
      electric stimulation is applied. This will consist in a standardized tetanic stimulation to&#xD;
      the ulnar nerve of the non-dominant forearm delivered by a routine nerve stimulator at a&#xD;
      frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds. Measurements of the&#xD;
      NOL Index, BIS, HR and MAP will continue during 3 minutes after (poststimulation period).&#xD;
      This window of recording has to be free of any other external stimulation as it could produce&#xD;
      noise disturbance on recorded values.&#xD;
&#xD;
      After the stimulation, all the monitors will be used to guide intraoperative administration&#xD;
      of hypnotic agents and analgesics. Total consumption of hypnotics and opioids will be&#xD;
      recorded for the duration of surgery. Postoperative assessment of pain and opioid consumption&#xD;
      will be done in post anesthesia care unit as exploratory outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled parallel open label study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delta NOL (no unit for the NOL index)</measure>
    <time_frame>From 1 minute before to 3 minutes after tetanic stimulation for each patient</time_frame>
    <description>To compare the variation of NOL (delta NOL) after tetanic stimulation under general anesthesia based on propofol versus sevoflurane</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delta Heart Rate (beat per minute)</measure>
    <time_frame>From 1 minute before to 3 minutes after tetanic stimulation for each patient</time_frame>
    <description>To compare the variation of heart rate after tetanic stimulation under general anesthesia based on propofol versus sevoflurane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta Mean Arterial Blood Pressure (unit: mmHg)</measure>
    <time_frame>From 1 minute before to 3 minutes after tetanic stimulation for each patient</time_frame>
    <description>To compare the variation of mean arterial blood pressure (MABP) after tetanic stimulation under general anesthesia based on propofol versus sevoflurane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta BIS (no unit for BIS index)</measure>
    <time_frame>From 1 minute before to 3 minutes after tetanic stimulation for each patient</time_frame>
    <description>To compare the variation of bispectral index (BIS) after tetanic stimulation under general anesthesia based on propofol versus sevoflurane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak value of NOL (no unit)</measure>
    <time_frame>From 1 minute before to 3 minutes after tetanic stimulation for each patient</time_frame>
    <description>To compare the peak value of NOL after tetanic stimulation under general anesthesia based on propofol versus sevoflurane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak value of Heart Rate (unit: beat per minute)</measure>
    <time_frame>From 1 minute before to 3 minutes after tetanic stimulation for each patient</time_frame>
    <description>To compare the peak value of heart rate after tetanic stimulation under general anesthesia based on propofol versus sevoflurane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak value of Mean Arterial Blood Pressure (unit: mmHg)</measure>
    <time_frame>From 1 minute before to 3 minutes after tetanic stimulation for each patient</time_frame>
    <description>To compare the peak value of mean arterial blood pressure (MABP) after tetanic stimulation under general anesthesia based on propofol versus sevoflurane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak value of BIS (no unit)</measure>
    <time_frame>From 1 minute before to 3 minutes after tetanic stimulation for each patient</time_frame>
    <description>To compare the peak value of bispectral index (BIS) after tetanic stimulation under general anesthesia based on propofol versus sevoflurane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for NOL for Propofol Versus Sevoflurane (no unit)</measure>
    <time_frame>From T0 (start stimulation) to 3 minutes after tetanic stimulation for each patient</time_frame>
    <description>To compare the area under the curve between propofol and sevoflurane between the beginning of stimulation and 3 minutes after stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for Heart Rate for Propofol Versus Sevoflurane (no unit)</measure>
    <time_frame>From T0 (start stimulation) to 3 minutes after tetanic stimulation for each patient</time_frame>
    <description>To compare the area under the curve between propofol and sevoflurane between the beginning of stimulation and 3 minutes after stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for Mean Arterial Blood Pressure for Propofol Versus Sevoflurane (no unit)</measure>
    <time_frame>From T0 (start stimulation) to 3 minutes after tetanic stimulation for each patient</time_frame>
    <description>To compare the area under the curve between propofol and sevoflurane between the beginning of stimulation and 3 minutes after stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for BIS for Propofol Versus Sevoflurane (no unit)</measure>
    <time_frame>From T0 (start stimulation) to 3 minutes after tetanic stimulation for each patient</time_frame>
    <description>To compare the area under the curve between propofol and sevoflurane between the beginning of stimulation and 3 minutes after stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Dose of Remifentanil (unit: mcg)</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Total dose of remifentanil in mcg from induction of anesthesia until tracheal extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Dose of Propofol (unit: mg)</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Total dose of propofol in mg from induction of anesthesia until tracheal extubation in Propofol group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Dose of Sevoflurane (unit: mL)</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Total dose of sevoflurane in mL from induction of anesthesia until tracheal extubation in Sevoflurane group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Dose of Hydromorphone in post-anesthesia care unit (PACU) (unit: mg)</measure>
    <time_frame>From entrance in post-anesthesia care unit until post-anesthesia care unit discharge, an average of 2 hours</time_frame>
    <description>Total dose of hydromorphone in mg in post-anesthesia care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-anesthesia care unit (PACU) Pain Scores at Rest (scale from 0 to 10)</measure>
    <time_frame>From entrance in post-anesthesia care unit until post-anesthesia care unit discharge, an average of 2 hours</time_frame>
    <description>Pain scores on a scale from 0 to 10 at rest in post-anesthesia care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-anesthesia care unit (PACU) Pain Scores during Cough (scale from 0 to 10)</measure>
    <time_frame>From entrance in post-anesthesia care unit until post-anesthesia care unit discharge, an average of 2 hours</time_frame>
    <description>Pain scores on a scale from 0 to 10 during cough effort in post-anesthesia care unit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Nociceptive Pain</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Propofol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction and maintenance of general anesthesia using propofol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction and maintenance of general anesthesia using sevoflurane</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>In the propofol group, general anesthesia will be induced using target-controlled infusion (TCI) of propofol and remifentanil. Marsh pharmacokinetic model will be used to set the initial target predicted effect-site concentration of propofol at 3.0 mcg/ml in flash mode. Simultaneously, target-controlled infusion of remifentanil will be started to reach an initial target predicted effect-site concentration of 3 ng/mL using the Minto pharmacokinetic model.&#xD;
After tracheal intubation, TCI of remifentanil is paused.</description>
    <arm_group_label>Propofol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>In the sevoflurane group, induction of general anesthesia will be carried out by spontaneous breathing through a mask while progressively opening up the dial of the sevoflurane vaporizer up to 8%. Like in the propofol group, target-controlled infusion of remifentanil is simultaneously started to reach an initial target predicted effect-site concentration of 3 ng/mL. Vaporizer is adjusted when gas equilibration reaches the patient-specific concentration 1.0 MAC of sevoflurane. After tracheal intubation, TCI of remifentanil is paused.</description>
    <arm_group_label>Sevoflurane group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA status I, II or III&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Elective surgery under general anesthesia.&#xD;
&#xD;
          -  Good understanding of English or French language&#xD;
&#xD;
        Non-inclusion Criteria&#xD;
&#xD;
          -  Ongoing Coronary artery disease&#xD;
&#xD;
          -  Patients with non-regular sinus cardiac rhythm, implanted pacemakers, prescribed&#xD;
             antimuscarinic agents, α2-adrenergic agonists, β1-adrenergic antagonists and&#xD;
             antiarrhythmic agents&#xD;
&#xD;
          -  Emergent surgery&#xD;
&#xD;
          -  Pregnancy/lactation&#xD;
&#xD;
          -  Preoperative hemodynamic disturbance&#xD;
&#xD;
          -  Central nervous system disorder (neurologic/head trauma/uncontrolled epileptic&#xD;
             seizures)&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Drug or alcohol abuse within the last 6 months&#xD;
&#xD;
          -  Chronic use of psychoactive drugs&#xD;
&#xD;
          -  Pre-operative chronic opioid use or chronic pain, equivalent to oxycodone 20mg per&#xD;
             oral, per day for more than 6 weeks&#xD;
&#xD;
          -  History of psychiatric diseases or psychological problems&#xD;
&#xD;
          -  Allergy or intolerance to any of the study drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unexpected difficult airway requesting excessive, possibly painful airway&#xD;
             manipulations.&#xD;
&#xD;
          -  Intraoperative unexpected complications requiring strong hemodynamic support&#xD;
             (transfusions, vasopressors, inotropes)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe Richebé</last_name>
    <phone>(514) 252-3400</phone>
    <phone_ext>4620</phone_ext>
    <email>philipperichebe@live.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadia Godin</last_name>
    <phone>514-252-3400</phone>
    <phone_ext>3193</phone_ext>
    <email>ngodin.hmr@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIUSSS de l'Est de l'Ile de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Richebé, MD, PhD</last_name>
      <phone>5147436558</phone>
      <email>philippe.richebe@umontreal.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ciusss de L'Est de l'Île de Montréal</investigator_affiliation>
    <investigator_full_name>Philippe Richebe</investigator_full_name>
    <investigator_title>Professor, MD, PhD, DESAR, Chair of Research</investigator_title>
  </responsible_party>
  <keyword>NOL index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nociceptive Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

